المؤلفون: Bergenstal, Richard M, Layne, Jennifer E, Zisser, Howard, Gabbay, Robert A, Barleen, Nathan A, Lee, Amy Armento, Majithia, Amit R, Parkin, Christopher G, Dixon, Ronald F

المصدر: Diabetes Technology & Therapeutics. 23(2)

مصطلحات موضوعية: Diabetes, Aging, Clinical Research, Obesity, Prevention, Nutrition, Management of diseases and conditions, 7.1 Individual care needs, Metabolic and endocrine, Adult, Blood Glucose, Blood Glucose Self-Monitoring, Diabetes Mellitus, Type 2, Female, Humans, Male, Middle Aged, Mobile Applications, Text Messaging, HbA1c, CGM, Digital health, Telemedicine, Telehealth, Type 2 diabetes, Clinical Sciences, Medical Physiology, Endocrinology & Metabolism

الوصف: The Onduo Virtual Diabetes Clinic (VDC) for people with type 2 diabetes (T2D) combines a mobile app, remote lifestyle coaching, connected devices, and live video consultations with board-certified endocrinologists. Adults with T2D (n = 594) who were evaluated by a VDC endocrinologist, remotely prescribed and mailed a real-time continuous glucose monitoring (rtCGM) device and used ≥1 sensor completed a CGM satisfaction questionnaire. The CGM satisfaction score was 4.5 ± 0.8 out of 5. Most respondents (94.7%) agreed/strongly agreed that they were comfortable inserting the sensor remotely and that rtCGM use improved understanding of the impact of eating (97.0%), increased diabetes knowledge (95.7%), and helped improve diabetes control when not wearing the sensor (79.4%). HbA1c (n = 372) decreased from 7.7% ± 1.6% to 7.1% ± 1.2% (P

وصف الملف: application/pdf

الوصول الحر: https://escholarship.org/uc/item/2297v2nhTest

المؤلفون: Danne, Thomas, Garg, Satish, Peters, Anne L, Buse, John B, Mathieu, Chantal, Pettus, Jeremy H, Alexander, Charles M, Battelino, Tadej, Ampudia-Blasco, F Javier, Bode, Bruce W, Cariou, Bertrand, Close, Kelly L, Dandona, Paresh, Dutta, Sanjoy, Ferrannini, Ele, Fourlanos, Spiros, Grunberger, George, Heller, Simon R, Henry, Robert R, Kurian, Martin J, Kushner, Jake A, Oron, Tal, Parkin, Christopher G, Pieber, Thomas R, Rodbard, Helena W, Schatz, Desmond, Skyler, Jay S, Tamborlane, William V, Yokote, Koutaro, Phillip, Moshe

المصدر: Diabetes Care. 42(6)

مصطلحات موضوعية: Biomedical and Clinical Sciences, Clinical Sciences, Obesity, Diabetes, 6.1 Pharmaceuticals, Evaluation of treatments and therapeutic interventions, 5.1 Pharmaceuticals, Development of treatments and therapeutic interventions, Metabolic and endocrine, Good Health and Well Being, Consensus, Diabetes Mellitus, Type 1, Diabetes Mellitus, Type 2, Diabetic Ketoacidosis, Glucose, Humans, Hypoglycemic Agents, Risk Management, Sodium, Sodium-Glucose Transporter 2 Inhibitors, Medical and Health Sciences, Endocrinology & Metabolism, Biomedical and clinical sciences, Health sciences

الوصف: Sodium-glucose cotransporter (SGLT) inhibitors are new oral antidiabetes medications shown to effectively reduce glycated hemoglobin (A1C) and glycemic variability, blood pressure, and body weight without intrinsic properties to cause hypoglycemia in people with type 1 diabetes. However, recent studies, particularly in individuals with type 1 diabetes, have demonstrated increases in the absolute risk of diabetic ketoacidosis (DKA). Some cases presented with near-normal blood glucose levels or mild hyperglycemia, complicating the recognition/diagnosis of DKA and potentially delaying treatment. Several SGLT inhibitors are currently under review by the U.S. Food and Drug Administration and European regulatory agencies as adjuncts to insulin therapy in people with type 1 diabetes. Strategies must be developed and disseminated to the medical community to mitigate the associated DKA risk. This Consensus Report reviews current data regarding SGLT inhibitor use and provides recommendations to enhance the safety of SGLT inhibitors in people with type 1 diabetes.

وصف الملف: application/pdf

الوصول الحر: https://escholarship.org/uc/item/9308m6w0Test

المؤلفون: Phillip, Moshe, Nimri, Revital, Bergenstal, Richard M, Barnard-Kelly, Katharine, Danne, Thomas, Hovorka, Roman, Kovatchev, Boris P, Messer, Laurel H, Parkin, Christopher G, Ambler-Osborn, Louise, Amiel, Stephanie A, Bally, Lia, Beck, Roy W, Biester, Sarah, Biester, Torben, Blanchette, Julia E, Bosi, Emanuele, Boughton, Charlotte K, Breton, Marc D, Brown, Sue A, Buckingham, Bruce A, Cai, Albert, Carlson, Anders L, Castle, Jessica R, Choudhary, Pratik, Close, Kelly L, Cobelli, Claudio, Criego, Amy B, Davis, Elizabeth, de Beaufort, Carine, de Bock, Martin I, DeSalvo, Daniel J, DeVries, J Hans, Dovc, Klemen, Doyle, Francis J, Ekhlaspour, Laya, Shvalb, Naama Fisch, Forlenza, Gregory P, Gallen, Geraldine, Garg, Satish K, Gershenoff, Dana C, Gonder-Frederick, Linda A, Haidar, Ahmad, Hartnell, Sara, Heinemann, Lutz, Heller, Simon, Hirsch, Irl B, Hood, Korey K, Isaacs, Diana, Klonoff, David C, Kordonouri, Olga, Kowalski, Aaron, Laffel, Lori, Lawton, Julia, Lal, Rayhan A, Leelarathna, Lalantha, Maahs, David M, Murphy, Helen R, Nørgaard, Kirsten, O'Neal, David, Oser, Sean, Oser, Tamara, Renard, Eric, Riddell, Michael C, Rodbard, David, Russell, Steven J, Schatz, Desmond A, Shah, Viral N, Sherr, Jennifer L, Simonson, Gregg D, Wadwa, R Paul, Ward, Candice, Weinzimer, Stuart A, Wilmot, Emma G, Battelino, Tadej

المصدر: Phillip, Moshe; Nimri, Revital; Bergenstal, Richard M; Barnard-Kelly, Katharine; Danne, Thomas; Hovorka, Roman; Kovatchev, Boris P; Messer, Laurel H; Parkin, Christopher G; Ambler-Osborn, Louise; Amiel, Stephanie A; Bally, Lia; Beck, Roy W; Biester, Sarah; Biester, Torben; Blanchette, Julia E; Bosi, Emanuele; Boughton, Charlotte K; Breton, Marc D; Brown, Sue A; . (2023). Consensus Recommendations for the Use of Automated Insulin Delivery (AID) Technologies in Clinical Practice. Endocrine reviews, 44(2), pp. 254-280. Oxford University Press 10.1210/endrev/bnac022

مصطلحات موضوعية: 610 Medicine & health

الوصف: The significant and growing global prevalence of diabetes continues to challenge people with diabetes (PwD), healthcare providers and payers. While maintaining near-normal glucose levels has been shown to prevent or delay the progression of the long-term complications of diabetes, a significant proportion of PwD are not attaining their glycemic goals. During the past six years, we have seen tremendous advances in automated insulin delivery (AID) technologies. Numerous randomized controlled trials and real-world studies have shown that the use of AID systems is safe and effective in helping PwD achieve their long-term glycemic goals while reducing hypoglycemia risk. Thus, AID systems have recently become an integral part of diabetes management. However, recommendations for using AID systems in clinical settings have been lacking. Such guided recommendations are critical for AID success and acceptance. All clinicians working with PwD need to become familiar with the available systems in order to eliminate disparities in diabetes quality of care. This report provides much-needed guidance for clinicians who are interested in utilizing AIDs and presents a comprehensive listing of the evidence payers should consider when determining eligibility criteria for AID insurance coverage.

وصف الملف: application/pdf

العلاقة: https://boris.unibe.ch/172712Test/

الإتاحة: https://doi.org/10.1210/endrev/bnac022Test
https://boris.unibe.ch/172712/1/bnac022.pdfTest
https://boris.unibe.ch/172712Test/

المؤلفون: Ceriello, Antonio, Rodbard, Helena W., Battelino, Tadej, Brosius, Frank, Cosentino, Francesco, Green, Jennifer, Ji, Linong, Kellerer, Monika, Koob, Susan, Kosiborod, Mikhail, Lalic, Nebojsa, Marx, Nikolaus, Nedungadi, T. P., Parkin, Christopher G., Rydén, Lars, Sheu, Wayne H., Standl, Eberhard, Vandvik, Per O., Schnell, Oliver

الوصف: In recent years, several novel agents have become available to treat individuals with type 2 diabetes (T2D), such as sodium-glucose cotransporter-2 inhibitors (SGLT-2i), tirzepatide, which is a dual glucose-dependent insulinotropic polypeptide receptor agonist (GIP RA)/glucagon-like peptide-1 receptor agonist (GLP-1 RA), and finerenone, a non-steroidal mineralocorticoid receptor antagonist (MRA) that confers significant renal and cardiovascular benefits in individuals with (CKD). New medications have the potential to improve the lives of individuals with diabetes. However, clinicians are challenged to understand the benefits and potential risks associated with these new and emerging treatment options. In this article, we discuss how use of network meta-analyses (NMA) can fill this need.

العلاقة: Cardiovascular Diabetology. 2023 Oct 13;22(1):277; http://hdl.handle.net/10852/105561Test; https://doi.org/10.1186/s12933-023-01993-3Test

الإتاحة: https://doi.org/10.1186/s12933-023-01993-3Test
http://hdl.handle.net/10852/105561Test

المؤلفون: Phillip, Moshe, Nimri, Revital, Bergenstal, Richard M., Barnard-Kelly, Katharine, Danne, Thomas, Hovorka, Roman, Kovatchev, Boris P., Messer, Laurel H., Parkin, Christopher G., Ambler-Osborn, Louise, Amiel, Stephanie A., Bally, Lia, Beck, Roy W., Biester, Sarah, Biester, Torben, Blanchette, Julia E., Bosi, Emanuele, Boughton, Charlotte K., Breton, Marc D., Brown, Sue A., Buckingham, Bruce A., Cai, Albert, Carlson, Anders L., Castle, Jessica R., Choudhary, Pratik, Close, Kelly L., Cobelli, Claudio, Criego, Amy B., Davis, Elizabeth, de Beaufort, Carine, de Bock, Martin I., DeSalvo, Daniel J., DeVries, J. Hans, Dovc, Klemen, Doyle, Francis J., Ekhlaspour, Laya, Shvalb, Naama Fisch, Forlenza, Gregory P., Gallen, Geraldine, Garg, Satish K., Gershenoff, Dana C., Gonder-Frederick, Linda A., Haidar, Ahmad, Hartnell, Sara, Heinemann, Lutz, Heller, Simon, Hirsch, Irl B., Hood, Korey K., Isaacs, Diana, Klonoff, David C., Kordonouri, Olga, Kowalski, Aaron, Laffel, Lori, Lawton, Julia, Lal, Rayhan A., Leelarathna, Lalantha, Maahs, David M., Murphy, Helen R., Nørgaard, Kirsten, O'Neal, David, Oser, Sean, Oser, Tamara, Renard, Eric, Riddell, Michael C., Rodbard, David, Russell, Steven J., Schatz, Desmond A., Shah, Viral N, Sherr, Jennifer L., Simonson, Gregg D., Wadwa, R. Paul, Ward, Candice, Weinzimer, Stuart A., Wilmot, Emma G., Battelino, Tadej

المصدر: Phillip , M , Nimri , R , Bergenstal , R M , Barnard-Kelly , K , Danne , T , Hovorka , R , Kovatchev , B P , Messer , L H , Parkin , C G , Ambler-Osborn , L , Amiel , S A , Bally , L , Beck , R W , Biester , S , Biester , T , Blanchette , J E , Bosi , E , Boughton , C K , Breton , M D , Brown , S A , Buckingham , B A , Cai , A , ....

مصطلحات موضوعية: automated insulin delivery, closed-loop, consensus recommendations, type 1 diabetes

الوصف: The significant and growing global prevalence of diabetes continues to challenge people with diabetes (PwD), healthcare providers, and payers. While maintaining near-normal glucose levels has been shown to prevent or delay the progression of the long-term complications of diabetes, a significant proportion of PwD are not attaining their glycemic goals. During the past 6 years, we have seen tremendous advances in automated insulin delivery (AID) technologies. Numerous randomized controlled trials and real-world studies have shown that the use of AID systems is safe and effective in helping PwD achieve their long-term glycemic goals while reducing hypoglycemia risk. Thus, AID systems have recently become an integral part of diabetes management. However, recommendations for using AID systems in clinical settings have been lacking. Such guided recommendations are critical for AID success and acceptance. All clinicians working with PwD need to become familiar with the available systems in order to eliminate disparities in diabetes quality of care. This report provides much-needed guidance for clinicians who are interested in utilizing AIDs and presents a comprehensive listing of the evidence payers should consider when determining eligibility criteria for AID insurance coverage.

وصف الملف: application/pdf

الإتاحة: https://doi.org/10.1210/endrev/bnac022Test
https://curis.ku.dk/portal/da/publications/consensus-recommendations-for-the-use-of-automated-insulin-delivery-technologies-in-clinical-practiceTest(6dc66ab2-5b1f-47ea-a8b8-b414f2b185d5).html
https://curis.ku.dk/ws/files/344330218/bnac022.pdfTest

المؤلفون: Do, Quoc Dat, Hásková, Aneta, Radovnická, Lucie, Konečná, Judita, Horová, Eva, Parkin, Christopher G., Grunberger, George, Prázný, Martin, Šoupal, Jan

المصدر: Diabetes, Obesity and Metabolism ; volume 26, issue 1, page 78-84 ; ISSN 1462-8902 1463-1326

الوصف: Aim To compare open‐source AndroidAPS (AAPS) and commercially available Control‐IQ (CIQ) automated insulin delivery (AID) systems in a prospective, open‐label, single‐arm clinical trial. Methods Adults with type 1 diabetes who had been using AAPS by their own decision entered the first 3‐month AAPS phase then were switched to CIQ for 3 months. The results of this treatment were compared with those after the 3‐month AAPS phase. The primary endpoint was the change in time in range (% TIR; 70‐80 mg/dL). Results Twenty‐five people with diabetes (mean age 34.32 ± 11.07 years; HbA1c 6.4% ± 3%) participated in this study. CIQ was comparable with AAPS in achieving TIR (85.72% ± 7.64% vs. 84.24% ± 8.46%; P = .12). Similarly, there were no differences in percentage time above range (> 180 and > 250 mg/dL), mean sensor glucose (130.3 ± 13.9 vs. 128.3 ± 16.9 mg/dL; P = .21) or HbA1c (6.3% ± 2.1% vs. 6.4% ± 3.1%; P = .59). Percentage time below range (< 70 and < 54 mg/dL) was significantly lower using CIQ than AAPS. Even although participants were mostly satisfied with CIQ (63.6% mostly agreed, 9.1% strongly agreed), they did not plan to switch to CIQ. Conclusions The CODIAC study is the first prospective study investigating the switch between open‐source and commercially available AID systems. CIQ and AAPS were comparable in achieving TIR. However, hypoglycaemia was significantly lower with CIQ.

الإتاحة: https://doi.org/10.1111/dom.15289Test

المؤلفون: McGill, Janet B., Hirsch, Irl B., Parkin, Christopher G., Aleppo, Grazia, Levy, Carol J., Gavin III, James R.

المصدر: Diabetes Therapy; May2024, Vol. 15 Issue 5, p1085-1098, 14p

مصطلحات موضوعية: TYPE 2 diabetes, INSULIN therapy, GLUCAGON-like peptide-1 receptor, GLUCAGON-like peptide-1 agonists, GLYCEMIC control

مستخلص: Early initiation of intensive insulin therapy has been demonstrated to be effective in controlling glycemia and possibly preserving beta-cell function. Innovations in insulin formulations and delivery systems continue. However, we have seen an acceleration in the development of new classes of diabetes medications for individuals with type 2 diabetes and obesity, such as, for example, glucagon-like peptide-1 receptor agonists (GLP-1 RAs). These formulations have been shown to confer significant benefits in achieving good glycemic control with reduced hypoglycemia risk, weight loss, and cardiorenal protection. Therefore, it is reasonable to question whether there is still a role for insulin therapy in the management of type 2 diabetes. However, there are clear limitations inherent to GLP-1 RA therapy, including high rates of suboptimal adherence and treatment discontinuation due to high cost and side effects, which diminish long-term efficacy, and supply issues. In addition, newer formulations have shown improvements in convenience and tolerability, and have been shown to be even more effective when used in conjunction with basal insulin. In this narrative review, we discuss current evidence that supports GLP-1 RA use in combination with insulin therapy and the potential pitfalls of reliance on GLP-1 RAs as a substitute for insulin therapy. [ABSTRACT FROM AUTHOR]

: Copyright of Diabetes Therapy is the property of Springer Nature and its content may not be copied or emailed to multiple sites or posted to a listserv without the copyright holder's express written permission. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.)

المؤلفون: Layne, Jennifer E., Jepson, Lauren H., Carite, Alexander M., Parkin, Christopher G., Bergenstal, Richard M.

المصدر: Diabetes Technology & Therapeutics ; ISSN 1520-9156 1557-8593

الإتاحة: https://doi.org/10.1089/dia.2024.0197Test

المؤلفون: Barnard-Kelly, Katharine, Marrero, David, de Wit, Maartje, Pouwer, Frans, Khunti, Kamlesh, Hermans, Norbert, Pierce, Jessica S., Laffel, Lori, Holt, Richard I.G., Battelino, Tadej, Naranjo, Diana, Fosbury, Jacqueline, Fisher, Lawrence, Polonsky, William, Weissberg-Benchell, Jill, Hood, Korey K., Schnell, Oliver, Messer, Laurel H., Danne, Thomas, Nimri, Revital, Skovlund, Soren E., Mader, Julia K., Sherr, Jennifer L., Schatz, Desmond, O'Neill, Simon, Doble, Emma, Town, Marissa, Lange, Karin, de Beaufort, Carine, Gonder-Frederick, Linda, Jaser, Sarah S., Liberman, Alon, Klonoff, David, ElSayed, Nuha A., Bannuru, Raveendhara R., Parkin, Christopher G., Snoek, Frank

المصدر: Barnard-Kelly , K , Marrero , D , de Wit , M , Pouwer , F , Khunti , K , Hermans , N , Pierce , J S , Laffel , L , Holt , R I G , Battelino , T , Naranjo , D , Fosbury , J , Fisher , L , Polonsky , W , Weissberg-Benchell , J , Hood , K K , Schnell , O , Messer , L H , Danne , T , Nimri , R , Skovlund , S E , Mader , J K , Sherr , J ....

الوصف: Diabetes is unique among chronic diseases because clinical outcomes are intimately tied to how the person living with diabetes reacts to and implements treatment recommendations. It is further characterised by widespread social stigma, judgement and paternalism. This physical, social and psychological burden collectively influences self-management behaviours. It is widely recognised that the individual's perspective about the impact of trying to manage the disease and the burden that self-management confers must be addressed to achieve optimal health outcomes. Standardised, rigorous assessment of mental and behavioural health status, in interaction with physical health outcomes is crucial to aid understanding of person-reported outcomes (PROs). Whilst tempting to conceptualise PROs as an issue of perceived quality of life (QoL), in fact health-related QoL is multi-dimensional and covers indicators of physical or functional health status, psychological and social well-being. This complexity is illuminated by the large number of person reported outcome measures (PROMs) that have been developed across multiple psychosocial domains. Often measures are used inappropriately or because they have been used in the scientific literature rather than based on methodological or outcome assessment rigour. Given the broad nature of psychosocial functioning/mental health, it is important to broadly define PROs that are evaluated in the context of therapeutic interventions, real-life and observational studies. This report summarises the central themes and lessons derived in the assessment and use of PROMs amongst adults with diabetes. Effective assessment of PROMs routinely in clinical research is crucial to understanding the true impact of any intervention. Selecting appropriate measures, relevant to the specific factors of PROs important in the research study will provide valuable data alongside physical health data.

العلاقة: https://research.vumc.nl/en/publications/209066bc-1bec-443a-b71b-3306de5e7ceaTest

الإتاحة: https://doi.org/10.1111/dme.15332Test
https://research.vumc.nl/en/publications/209066bc-1bec-443a-b71b-3306de5e7ceaTest
http://www.scopus.com/inward/record.url?scp=85193316206&partnerID=8YFLogxKTest

المؤلفون: Gavin, James R., Rodbard, Helena W., Battelino, Tadej, Brosius, Frank, Ceriello, Antonio, Cosentino, Francesco, Giorgino, Francesco, Green, Jennifer, Ji, Linong, Kellerer, Monika, Koob, Susan, Kosiborod, Mikhail, Lalic, Nebojsa, Marx, Nikolaus, Prashant Nedungadi, T., Parkin, Christopher G., Topsever, Pinar, Rydén, Lars, Huey-Herng Sheu, Wayne, Standl, Eberhard, Olav Vandvik, Per, Schnell, Oliver

المساهمون: DexCom Inc, Eli Lilly and Company, Boehringer Ingelheim International GmbH, AstraZeneca Pharmaceuticals LP, Bayer AG

المصدر: Diabetes Research and Clinical Practice ; volume 211, page 111666 ; ISSN 0168-8227

مصطلحات موضوعية: Endocrinology, General Medicine, Endocrinology, Diabetes and Metabolism, Internal Medicine

الإتاحة: https://doi.org/10.1016/j.diabres.2024.111666Test
https://api.elsevier.com/content/article/PII:S016882272400576X?httpAccept=text/xmlTest
https://api.elsevier.com/content/article/PII:S016882272400576X?httpAccept=text/plainTest